Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Debt (2016 - 2025)

BioCorRx's Total Debt history spans 11 years, with the latest figure at $69803.0 for Q3 2025.

  • For Q3 2025, Total Debt fell 94.25% year-over-year to $69803.0; the TTM value through Sep 2025 reached $69803.0, down 94.25%, while the annual FY2024 figure was $71029.0, 92.89% down from the prior year.
  • Total Debt for Q3 2025 was $69803.0 at BioCorRx, down from $71029.0 in the prior quarter.
  • Across five years, Total Debt topped out at $3.1 million in Q2 2022 and bottomed at $31580.0 in Q4 2021.
  • The 5-year median for Total Debt is $1.1 million (2023), against an average of $1.4 million.
  • The largest YoY upside for Total Debt was 804.6% in 2021 against a maximum downside of 98.68% in 2021.
  • A 5-year view of Total Debt shows it stood at $31580.0 in 2021, then skyrocketed by 9721.92% to $3.1 million in 2022, then plummeted by 67.79% to $999088.0 in 2023, then crashed by 92.89% to $71029.0 in 2024, then dropped by 1.73% to $69803.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Total Debt are $69803.0 (Q3 2025), $71029.0 (Q4 2024), and $1.2 million (Q3 2024).